Seeking Alpha

Merck & Co Inc. (MRK)

  • Jun. 3, 2013, 3:49 PM
    Goldman Sachs isn't buying into the lovefest on Merck's (MRK +3.7%) presentation today on its oncology offerings. Analyst Jami Rubin notes that Lambro is a strong single agent immuno-oncology drug but the company is missing out on "combo potential," which are likely to take the majority share of the immuno-oncology market.
    | Jun. 3, 2013, 3:49 PM | Comment!
  • Jun. 3, 2013, 11:43 AM
    Amgen (AMGN -3.1%) slips today as analysts give a muted response to its experimental skin-cancer drug, T-Vec, despite delivering better-than-expected study data at ASCO. The problem is a new class of PD-1 immunotherapy drugs from Merck (MRK) and Bristol-Myers (BMY) are dominating the field. RBC predicts they'll "eventually usher in new standard of care" for melanoma, and limiting T-Vec's sales potential to only around $300M to $500M annually - which isn't much considering the multibillion-dollar market potential for PD-1 drugs.
    | Jun. 3, 2013, 11:43 AM | Comment!
  • Jun. 3, 2013, 8:19 AM
    Merck (MRKgains 3.9% premarket after an early-stage study on its skin cancer drug labrolizumab shows it shrinking tumors in 38% of advanced melanoma patients. The results were presented yesterday at the ASCO annual meeting. The drug could compete with Bristol-Myers Squibb's novolumab, but BMY is showing no ill effect, +2.7% premarket.
    | Jun. 3, 2013, 8:19 AM | Comment!
  • May 31, 2013, 5:43 AM
    A dispute is taking place within the FDA over whether a class of blockbuster cardiovascular drugs called angiotensin receptor blockers ((ARBs)) significantly increase the risk of cancer. On one side is Thomas Marciniak, who believes they do, and on the other are his bosses, who think the medicines are safe. Companies that make ARBs, which generated $7.6B in U.S. sales last year, include Novartis (NVS), Merck (MRK), Sanofi (SNY), Bristol-Myers Squibb (BMY) and AstraZeneca (AZN).
    | May 31, 2013, 5:43 AM | Comment!
  • May 28, 2013, 4:59 PM
    Merck (MRK) declares $0.43/share quarterly dividend, in line with previous. Forward yield 3.61%. For shareholders of record June 17. Payable July 18.Ex-div date June 13. (PR)
    | May 28, 2013, 4:59 PM | Comment!
  • May 28, 2013, 8:10 AM
    Add Eli Lilly (LLY) to Jefferies' big pharma upgrades, as the company is raised to Hold from Underperform (price target to $49 from $44) on a lack of near term downside risks and a healthy dividend. Nevertheless, expect FY14 EPS to come in 5-10% below consensus, analyst Jeff Holford says. Meanwhile, Merck (MRK), Abbott (ABT), and Novartis (NVS) are all top "restructuring plays." Jefferies says "the probability of significant spin-outs" for MRK should increase in 2014 and puts a sum-of-the-parts valuation of $54.30 on the stock.
    | May 28, 2013, 8:10 AM | Comment!
  • May 28, 2013, 7:02 AM
    Three Big Pharma upgrades: Jefferies takes Merck (MRK) and Bayer (BAYRY.PK) to Buy from Hold and Deutsche Bank lifts GlaxoSmithKline (GSK) to Buy from Hold.
    | May 28, 2013, 7:02 AM | 3 Comments
  • May 24, 2013, 12:06 PM
    Cubist Pharmaceuticals (CBST -1.5%) slips on a downgrade to Neutral on valuation at Janney Capital. Despite the downgrade - not to mention a 36% runup in the shares since last November - the firm raises its price target on the stock by another 10% to $55 from $50. Separately, CBST's CEO Mike Bonney is scheduled to present at Jefferies 2013 Global Healthcare Conference on Monday, June 3, to discuss it's pipeline, financial outlook, and recentdevelopments. Tune into the live presentation here: (Webcast)
    | May 24, 2013, 12:06 PM | Comment!
  • May 24, 2013, 8:18 AM
    Janney Montgomery Scott cuts Cubist Pharmaceuticals (CBST) to Neutral and takes its price target to $50 from $55, bringing its rating and PT largely in line with those of Cantor's Irina Rivkind who upgraded the stock to Hold from Sell (price target $49) on Tuesday.
    | May 24, 2013, 8:18 AM | Comment!
  • May 23, 2013, 5:26 PM
    Merck (MRK) provides an update on its clinical trials for preladenant, an investigational compound for the treatment of Parkinson's disease. An initial review of data from three separate Phase III trials showed no evidence of efficacy when compared with placebo, therefore MRK says it will discontinue the program and no longer plans to pursue any regulatory filings. Shares -0.4% AH.
    | May 23, 2013, 5:26 PM | Comment!
  • May 23, 2013, 3:11 PM
    Chatter says trading desks are busy with corporate buyback activity today as CFOs take advantage of a little selling to put repurchase plans into action. AAPL is the gorilla, having bumped its authorization to $60B from $10B. Others of note include: LyondellBasel (LYB), Merck (MRK) - which just entered an accelerated repurchase program, NetApp (NTAP), Northrop Grumman (NOC), Macy's (M), and Delta (DAL). There's also IBM - long with a reputation for issuing debt at lows in yield. Is their equity timing as good?
    | May 23, 2013, 3:11 PM | 6 Comments
  • May 22, 2013, 3:17 PM
    An FDA panel has voted 12-4 in favor of Merck's (MRK -1.2%) insomnia drug Suvorexant, saying it helps people stay asleep.
    | May 22, 2013, 3:17 PM | 1 Comment
  • May 21, 2013, 5:50 PM
    Merck (MRK) says it's entered into an accelerated share repurchase agreement with Goldman Sachs to repurchase $5B worth of stock, as the company looks to alternative methods for increasing shareholder value. The company has been dealing with the loss of exclusivity for its blockbuster asthma-and-allergy treatment Singulair, leading to generic competition that wiped out much of the drug's more than $5B in peak annual sales. Shares +1% AH.
    | May 21, 2013, 5:50 PM | Comment!
  • May 21, 2013, 9:46 AM
    Cantor Fitzgerald's Irina Rivkind upgrades Cubist Pharmaceuticals (CBST +5%) to hold from sell (price target raised to $49 from $40) saying concerns about generic competition have abated. Rivkind also notes that investors have plenty of time to wait for "a more attractive entry point," as the next big catalyst for the company is hospital pneumonia data not due until 2015.
    | May 21, 2013, 9:46 AM | Comment!
  • May 20, 2013, 3:37 PM
    Cubist Pharmaceuticals (CBST +11.3%) spikes to session highs. The move appears relates to an apparent Markman ruling on Hospira (HSP +0.7%, which has a generic version of Cubist's drug Cubicin. Seeking Alpha contributor PropThink noted last week that the ruling would likely be a 'clearing event' for the company.
    | May 20, 2013, 3:37 PM | Comment!
  • May 16, 2013, 12:55 PM
    Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY.
    | May 16, 2013, 12:55 PM | 3 Comments
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.